Purple Day® - March 25th!

The past year has been one full of changes and we've got a slightly minor one to announce regarding this year's Purple Day® in Ireland.

Instead of March 26th this year, we will be marking Purple Day® in Ireland on March 25th. The reason we have moved Purple Day® is because this year, the day has fallen on the same day as the Irish Cancer Society's Daffodil Day. 

Preliminary findings of International Study highlights impact of pandemic on people with epilepsy.

During the summer, our colleagues in SUDEP Action and researchers from the University of Oxford conducted an international survey on the impact COVID-19 is having on people with epilepsy; their families; and their healtcare providers (in terms of delivering services for people with epilepsy). Dr Danny Costello (Cork) and Prof Norman Delanty (Beaumont) are Irish collaborators on this international study.

Epilepsy Ireland to fund new study focused on issue of Free Travel

We are delighted to announce that we have approved research funding for a new study which will investigate the societal impact for people with epilepsy of losing a driving license. The research will take place at FutureNeuro, led by Prof. Norman Delanty; Consultant Neurologist at Beaumont Hospital and Registrar Dr. Stephen Klaus.

FINTEPLA (Fenfluramine) approved by EU Commission for use in Dravet Syndrome

The European Commission has approved the use of a new drug as an add-on therapy for the treatment of Dravet Syndrome in patients 2 years and older.

The Commission’s approval of FINTEPLA (Fenfluramine) will mean that the drug’s manufacturers can now apply to European member states regulatory authorities to make the drug available and/or reimbursed  in that country.